Tryptamine psilocin treatment ruled safe in IV infusion during early trial

Tryptamine Therapeutics Ltd (ASX:TYP) has achieved a major milestone in assessment of its use of hallucinogen psilocin to treat illnesses and various psychological conditions, with a Safety Committee ruling the company’s IV-infused psilocin was safe among health volunteer participants dosed in a clinical setting.

Under the trial, 11 participants were dosed with TRP-8803 via IV-infusion at varying levels for up to 150 minutes.

The decision marked the end of the Phase 1b Healthy Human Volunteer study for the IV-infusion, TRP-8803. The company is now moving into a through assessment of the trial data in preparation for a broader Phase 2 trial.

Further development will in part be shaped by TYP’s success in Phase 2a trials for an oral psilocybin treatment – TRP-8802 – after it revealed strong health outcomes for patients with both Binge Eating Disorder and Fibromyalgia in respective trials.

Chief executive officer Jason Carroll said the next phase of the Tryptamine assessment would enable TYP to check the qualities and benefits of the treatment to patients.

“The safety clearance provided by the SRC on TRP-8803 is a major milestone for the company,” he said.

“It further validates Tryp’s approach to drug development and also serves as a considerable de-risking catalyst moving forward.

“Work will now focus on finalising results from the Phase 1b study.

“This will allow the company to gain a broader understanding of the benefits TRP-8803 may provide to patients, refine and optimise the pharmacokinetic profile for the infusion of psilocin to achieve more precise blood levels and take steps to move TPR-8803 into a Phase 2 patient study for its first specific indication.”

TYP shares rose on the news, and at 12:21 AEDT, they were trading at 2.2 cents – a rise of 9.99% since the market opened.

Join the discussion. See what HotCopper users are saying about TYP and be part of the conversations that move the markets.

The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.